5-Bromo and 5-fluoro-2',3'-dideoxycytidine have been found to be active in the DTP anti-HIV screening program at FCRF. 2'-Fluoro-2',3'-dideoxyarabinosyl adenine is not only as active and potent as ddA in anti-HIV tests, it is completely stable to the acid catalyzed glycosidic cleavage which occurs so rapidly with ddA. Oral studies in the dog showed 83% bioavailability for the fluoro analogue but only 30% for ddA. Two five-member ring analogues of the fermentation product, oxetanocin, were prepared. The first had no cellular protective properties. The second is under evaluation.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CM006173-04
Application #
3916557
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Cancer Treatment
Department
Type
DUNS #
City
State
Country
United States
Zip Code